SBE13 | whatman (沃特曼)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SBE13

SBE13 是一种有效的，选择性的 Plk1 抑制剂，IC₅₀ 值为 200 pM，对 Plk2 (IC₅₀>66 μM) 或 Plk3 (IC₅₀=875 nM) 的作用较弱。

SBE13 Chemical Structure

CAS No. : 775294-82-1

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

SBE13 的其他形式现货产品:

SBE13 Hydrochloride

生物活性

SBE13 is a potent and selective Plk1 inhibitor, with an IC₅₀ of 200 pM; SBE13 poorly inhibits Plk2 (IC₅₀>66 μM) or Plk3 (IC₅₀=875 nM).

IC₅₀ & Target

PLK1

200 pM (IC₅₀)

PLK3

875 nM (IC₅₀)

体外研究
(In Vitro)

SBE13 significantly reduce cell proliferation and induce apoptosis in HeLa cells, with an EC₅₀ of 18 μM^[1]. SBE13 (1-100 μM) shows no effect on Caspase 3/7 activity in NIH-3T3 cells. SBE13 (66 and 100 μM) does not change morphology after treatment of primary cells. SBE13 (10 and 100 μM) reduces pRb staining in primary cells, and this indicates a G0/G1 arrest^[2]. SBE13 (66 and 100 μM) increases levels of cyclin B1, phospho histone H3, Wee1, Emi1 and securin, and results in cleavage of Cdc27 in HeLa cells. SBE13 (10 and 100 μM) also induces apoptosis of HeLa cells^[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

442.94

Formula

C₂₄H₂₇ClN₂O₄

CAS 号

775294-82-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Keppner S, et al. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem. 2009 Nov;4(11):1806-9.

[2]. Keppner S, et al. Fate of primary cells at the G?/S boundary after polo-like kinase 1 inhibition by SBE13. Cell Cycle. 2011 Feb 15;10(4):708-20. Epub 2011 Feb 15.

[3]. Keppner S, et al. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010 Feb 15;9(4):761-73. Epub 2010 Feb 16.

Kinase Assay ^[1]	To assay Plk1 kinase activity, cells are lysed after 13 h release in the presence of SBE13 after double thymidine block and kinase is immunoprecipitated from lysates using antibodies. In brief, for each immunoprecipitation 800 μg of total protein are incubated with Plk1 antibody cocktail (1.5 μg) for 2 h at 4°C on a rotator. Immunoprecipitated protein is collected using Protein A/G Agarose beads. Plk1 immunoprecipitates are incubated with casein (1 μg) and with [γ-³²P]ATP (1 μCi) for 30 min at 37°C in kinase buffer. Products from the kinase assays are fractionated on 10 % bis-tris-polyacrylamide gels, and phosphorylated substrate is visualized by autoradiography after an exposure of 12-36 h. Equal amounts of immunoprecipitates are subjected to Western blot analysis to confirm equal loading of Plk1 protein in kinase reactions^[1]. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Keppner S, et al. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem. 2009 Nov;4(11):1806-9. [2]. Keppner S, et al. Fate of primary cells at the G?/S boundary after polo-like kinase 1 inhibition by SBE13. Cell Cycle. 2011 Feb 15;10(4):708-20. Epub 2011 Feb 15. [3]. Keppner S, et al. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010 Feb 15;9(4):761-73. Epub 2010 Feb 16.

Kinase Assay
^[1]

To assay Plk1 kinase activity, cells are lysed after 13 h release in the presence of SBE13 after double thymidine block and kinase is immunoprecipitated from lysates using antibodies. In brief, for each immunoprecipitation 800 μg of total protein are incubated with Plk1 antibody cocktail (1.5 μg) for 2 h at 4°C on a rotator. Immunoprecipitated protein is collected using Protein A/G Agarose beads. Plk1 immunoprecipitates are incubated with casein (1 μg) and with [γ-³²P]ATP (1 μCi) for 30 min at 37°C in kinase buffer. Products from the kinase assays are fractionated on 10 % bis-tris-polyacrylamide gels, and phosphorylated substrate is visualized by autoradiography after an exposure of 12-36 h. Equal amounts of immunoprecipitates are subjected to Western blot analysis to confirm equal loading of Plk1 protein in kinase reactions^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Keppner S, et al. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem. 2009 Nov;4(11):1806-9.

[2]. Keppner S, et al. Fate of primary cells at the G?/S boundary after polo-like kinase 1 inhibition by SBE13. Cell Cycle. 2011 Feb 15;10(4):708-20. Epub 2011 Feb 15.

[3]. Keppner S, et al. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010 Feb 15;9(4):761-73. Epub 2010 Feb 16.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务